Translational Research in Gastric Malignancy

Sara M. Johnson, B. Mark Evers

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

This article discusses recent advances in gastric cancer research that have improved treatment and outcomes of gastric malignancy, or have the potential to do so. The significance of Helicobacter pylori infection and eradication, immunology, host genetics, proto-oncogenes, and epigenetic alterations in gastric cancer are discussed. Abnormal signaling through growth factor pathways (tyrosine kinases and gastrointestinal peptides) presents ample opportunities for therapeutic intervention that are currently being tested in clinical trials. Drugs targeting abnormal epigenetic changes, such as DNA hypermethylation and histone deacetylation, are also on the horizon, although most of this research is still in the preclinical phase. The potential prognostic implications of genetics and immunology in gastric cancer prognosis are also reviewed.

Original languageEnglish (US)
Pages (from-to)323-340
Number of pages18
JournalSurgical Oncology Clinics of North America
Volume17
Issue number2
DOIs
StatePublished - Apr 1 2008

Fingerprint

Translational Medical Research
Stomach Neoplasms
Stomach
Allergy and Immunology
Epigenomics
Neoplasms
Proto-Oncogenes
Helicobacter Infections
Drug Delivery Systems
Research
Helicobacter pylori
Histones
Protein-Tyrosine Kinases
Intercellular Signaling Peptides and Proteins
Clinical Trials
Peptides
DNA
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Translational Research in Gastric Malignancy. / Johnson, Sara M.; Evers, B. Mark.

In: Surgical Oncology Clinics of North America, Vol. 17, No. 2, 01.04.2008, p. 323-340.

Research output: Contribution to journalReview article

@article{65ba4cdb9b1f4d6993e7798eff909e6a,
title = "Translational Research in Gastric Malignancy",
abstract = "This article discusses recent advances in gastric cancer research that have improved treatment and outcomes of gastric malignancy, or have the potential to do so. The significance of Helicobacter pylori infection and eradication, immunology, host genetics, proto-oncogenes, and epigenetic alterations in gastric cancer are discussed. Abnormal signaling through growth factor pathways (tyrosine kinases and gastrointestinal peptides) presents ample opportunities for therapeutic intervention that are currently being tested in clinical trials. Drugs targeting abnormal epigenetic changes, such as DNA hypermethylation and histone deacetylation, are also on the horizon, although most of this research is still in the preclinical phase. The potential prognostic implications of genetics and immunology in gastric cancer prognosis are also reviewed.",
author = "Johnson, {Sara M.} and Evers, {B. Mark}",
year = "2008",
month = "4",
day = "1",
doi = "10.1016/j.soc.2008.01.001",
language = "English (US)",
volume = "17",
pages = "323--340",
journal = "Surgical Oncology Clinics of North America",
issn = "1055-3207",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Translational Research in Gastric Malignancy

AU - Johnson, Sara M.

AU - Evers, B. Mark

PY - 2008/4/1

Y1 - 2008/4/1

N2 - This article discusses recent advances in gastric cancer research that have improved treatment and outcomes of gastric malignancy, or have the potential to do so. The significance of Helicobacter pylori infection and eradication, immunology, host genetics, proto-oncogenes, and epigenetic alterations in gastric cancer are discussed. Abnormal signaling through growth factor pathways (tyrosine kinases and gastrointestinal peptides) presents ample opportunities for therapeutic intervention that are currently being tested in clinical trials. Drugs targeting abnormal epigenetic changes, such as DNA hypermethylation and histone deacetylation, are also on the horizon, although most of this research is still in the preclinical phase. The potential prognostic implications of genetics and immunology in gastric cancer prognosis are also reviewed.

AB - This article discusses recent advances in gastric cancer research that have improved treatment and outcomes of gastric malignancy, or have the potential to do so. The significance of Helicobacter pylori infection and eradication, immunology, host genetics, proto-oncogenes, and epigenetic alterations in gastric cancer are discussed. Abnormal signaling through growth factor pathways (tyrosine kinases and gastrointestinal peptides) presents ample opportunities for therapeutic intervention that are currently being tested in clinical trials. Drugs targeting abnormal epigenetic changes, such as DNA hypermethylation and histone deacetylation, are also on the horizon, although most of this research is still in the preclinical phase. The potential prognostic implications of genetics and immunology in gastric cancer prognosis are also reviewed.

UR - http://www.scopus.com/inward/record.url?scp=41149108569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149108569&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2008.01.001

DO - 10.1016/j.soc.2008.01.001

M3 - Review article

C2 - 18375355

AN - SCOPUS:41149108569

VL - 17

SP - 323

EP - 340

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

IS - 2

ER -